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Abstract
In our search for natural products with a broad spectrum of antifungal activity as lead compounds for novel treatments for mycoses, we
have isolated echinocandin-type lipopeptide FR901379 and lipopeptidolactone FR901469, as novel water-soluble antifungal agents that
inhibit the synthesis of 1,3-h-glucan, a key component of the fungal cell wall. Since the cell wall is a feature unique to fungi and is not
present in nonfungal eukaryotic cells, inhibitors of the synthesis of fungal cell wall components such as 1,3-h-glucan have potential for
selective toxicity to fungi and not to the host. In this short review, we describe efforts directed at synthetic modification of FR901469 and
FR901379 with the ultimate goal of identifying new entities with suitable profiles as development candidate compounds. The main thrust of
our work to date has been replacement of the highly flexible lipophilic side chains of the natural products with a view to reducing the
hemolytic potential associated with these compounds, and to enhance chemical stability and/or in vivo antifungal efficacy. As a result of these
efforts, we recently discovered a novel analog, FK463 (micafungin). Micafungin is currently in phase III clinical trials worldwide as a
parenteral agent for various mycoses, and a new drug application (NDA) was recently filed in Japan. D 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Fungal diseases in humans can be classified into (a)
allergic reactions to fungal proteins, (b) toxic reactions to
toxins present in certain fungi and (c) infections (mycoses).
By far the most serious and difficult to diagnose and treat,
mycoses come in many forms. Otherwise healthy individ-
uals are susceptible to a host of superficial, cutaneous,
subcutaneous, and in certain instances, systemic infections
that cause a variety of conditions ranging from Athletes foot
and nail infections to severe life-threatening disseminated
disease (e.g. histoplasmosis). On the other hand, immuno-
compromised individuals are susceptible to a large number
of opportunistic systemic mycoses, resulting from the
inability of host immune response to fight off attack from
normally benign environmental fungal pathogens. Indeed,
the last 20 years has witnessed a remarkable increase in the
incidence of deep-seated, disseminated mycoses [1]. The
reasons are manifold; however, the advent of aggressive
cancer chemotherapy, highly effective immunosuppressants
for organ transplantation, widespread use of powerful broad
spectrum antibacterial agents and the explosion in the
number of cases of human immunodeficiency virus (HIV)
infection have all contributed to the increase in life-threat-
ening fungal disease [2]. Furthermore, ongoing demo-
graphic trends would tend to strongly suggest that the
number of fungal infections will continue to increase due to
the aging of the population in developed countries [3].
Whilst difficulty in diagnosis of fungal infections and
delays in initiation of treatment are important factors, drugs
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Abbreviations: MIC, minimum inhibitory concentration; IC50, 50%
inhibitory concentration; ED50, 50% effective dose; NDA, new drug
application; HIV, human immunodeficiency virus; MLC, minimum lytic
concentration; BOC, tert-butoxycarbonyl; SCID Mouse, severe combined
immunodeficient mouse; PCP, Pneumocystis carinii-associated pneumonia;
Amp-B, amphotericin B; ITCZ, itraconazole; CFU, colony forming units;
FLCZ, fluconazole; AcOH, acetic acid; MeOH, methanol; THF, tetrahy-
drofuran; EtOAc, ethyl acetate; DMF, N,N-dimethylformamide; TFA,
trifluoroacetic Acid; HOBT, 1-hydroxybenzotriazole; WSCD.HCl, 1-
ethyl-3-dimethylaminopropylcarbodiimide hydrochloride; EtNiPr2, diiso-
propylethylamine; LiOH, lithium hydroxide; Z, benzyloxycarbonyl; MTPA,
a-methoxy-a-(trifluoromethyl)phenylacetic acid
* Tel.: +81-6-6390-1285; fax: +81-6-6304-5435.
E-mail address: david_barrett@po.fujisawa.co.jp (D. Barrett).
www.bba-direct.com
Biochimica et Biophysica Acta 1587 (2002) 224–233
for effective treatment of these emerging infections are in
short supply, thereby contributing to a high mortality rate.
Available drugs are essentially limited to the polyene natural
product amphotericin B [4,5] and various newer lipid
formulations [6], the azole compounds such as fluconazole
and itraconazole, and flucytosine (5-fluorocytosine) (Fig. 1).
These established agents suffer from a number of limitations
that can render their use difficult; for example, dose-limiting
nephrotoxicity associated with amphotericin B, rapid devel-
opment of resistance with flucytosine, drug–drug interac-
tions, fungistatic mode of action and resistance development
with the azoles. There is thus an urgent need for new
antifungals with a broad, fungicidal spectrum of action,
and with fewer dose-limiting side effects [7,8]. Whilst a
number of lipid-based formulations of amphotericin B have
been shown to be effective in ameliorating the toxic liabil-
ities associated with this agent, and a number of new azoles
are in the final stages of clinical development, the funda-
mental problems described above remain. Accordingly, it is
particularly imperative that we bring agents to the clinic that
have new mechanisms of action and have good, broad-
spectrum, cidal antifungal activity.
2. Natural product screening: novel antifungal agents
As a part of our efforts to discover new compounds with
potential as lead compounds for optimization studies lead-
ing to novel antifungal candidates, we first must answer a
simple key question: how do we identify and select a lead
Fig. 1. Major available drugs for systemic mycoses.
Fig. 2. Antifungal natural products discovered at Fujisawa.
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compound for further study? This is an important question
as it is clearly critical that any potential compound must
meet a number of criteria, otherwise the chances of ultimate
success will not be high. The questions that we ask when
selecting compounds for further investigation are as follows:
(1) Is the compound structurally novel? (2) Is the mecha-
nism of action novel and/or potentially useful? (3) Is in-
trinsic biological activity good? (4) Is clinical proof of con-
cept possible? (5) Is chemical modification/optimization of
the structure possible? It has become clear over a number of
years that all of these questions are critical and impact
greatly upon the chances of final success.
Since natural products have been proven to be an excel-
lent source of novel chemical entities, we have employed
screening of microbial extracts in our search for compounds
that match the criteria discussed above, and have disclosed a
number of structurally unique biologically active materials.
In the course of screening for novel antifungal antibiotics,
Fujisawa scientists have previously described the isolation of
antifungals such as chryscandin [9], chaetiacandin [10],
pyrrolnitrin [11], FR900848 [12] and FR109615 [13,14]
(Fig. 2). Whilst pyrrolnitrin is marketed in Japan for topical
indications, the other natural products had various limitations
in terms of spectrum of in vitro activity, in vivo activity,
water-solubility, lack of success in the chemical modification
studies, mechanism of action limitations and potential for
resistance development.
More recently, we have been engaged in the search for
water-soluble inhibitors of fungal 1,3-h-D-glucan synthase
[15], an enzyme critical to the synthesis of 1,3-h-D-glucan, a
major component of the cell wall of a number of key
pathogenic fungii [16]. The fungal cell wall is an attractive
target for the discovery of new antifungal agents [17],
primarily because it is essential for the viability of fungal
cells, and also because the fungal cell wall has no counterpart
in mammalian cells. Accordingly, compounds that selec-
tively target the biosynthesis of key components of the fungal
cell wall have potential to be nontoxic to mammalian hosts.
As a result of our continuous screening of microbial
extracts, we have discovered two unique, water-soluble
antifungals that express their activity by inhibition of the
synthesis of 1,3-h-D-glucan (Fig. 3). FR901379 is the first
example of a naturally water-soluble echinocandin deriva-
tive [18,19]. This natural product displays excellent water-
solubility by virtue of the presence of a sulfate moiety on the
homotyrosine group. FR901469 is the first example of a
new type of 1,3-h-glucan synthase inhibitor based upon a
40-membered cyclic lipopeptidolactone structure [20–22].
FR901469 also displays excellent water-solubility.
In this short review, we briefly describe some of our efforts
directed at synthetic modification of FR901469 and
FR901379. The main thrust of our work has been replace-
ment of the highly flexible lipophilic side chains and/or
chemical derivatization with a view to reducing the hemolytic
potential associated with the natural products, and to enhance
chemical stability and/or in vivo antifungal efficacy. As a
result of these efforts, we have discovered a novel analog,
FK463 (micafungin), which is currently in worldwide phase
III clinical trials as a parenteral agent for various mycoses.
3. Discovery and biological activity of FR901469 and
related derivatives
FR901469 was isolated as a hydrochloride salt from an
unidentified fungus no. 11243 [20]. This compound dis-
played water solubility of > 50 mg/ml, which compares with
Fig. 3. Water-soluble antifungal natural products discovered at Fujisawa.
Table 1
FR901469, a water-soluble lipopeptidolactone
h-1,3-glucan synthase inhibition (from C. albicans 6406)
Compound IC50 (Ag/ml)
FR901469 0.05
FR901379 0.7
Echinocandin B 2.6
Cilofungin 2.9
Papulacandin B 2.5
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0.008 mg/ml for echinocandin B, the prototype 1,3-h-
glucan synthase inhibitor. Furthermore, inhibition of the
enzyme from Candida albicans 6406 showed an IC50 of
0.05 Ag/ml, significantly more potent than echinocandin B
and papulacandin B (Table 1). The antifungal activity of
FR901469 is also excellent (Table 2), however, hemolytic
activity is high and comparable to echinocandin B, indicat-
ing the potential for drug–erythrocyte interactions and
hemolysis under in vivo conditions, especially in the multi-
ple dose regimens of usual drug treatment protocols. Early
work on echinocandin B indicated that major toxic liabilities
resulted from its high hemolytic potential [23,24]. Minimum
lytic concentration (MLC) for FR901469 was 250 Ag/ml,
compared to 125 Ag/ml for echinocandin B. Reduction of
hemolysis was considered critical in order to improve the
overall profile of this natural product, since echinocandin B
was unsuitable as a development candidate due to its
hemolysis and toxicity. An additional notable structural
feature of FR901469 is the juxtaposition of an ornithine
amino group adjacent to a lactone moiety. This feature leads
to a pH-dependent ring opening process, which whilst not
effecting in vivo antifungal potency significantly, presum-
ably due to amino group protonation at physiological pH, is
potentially a source of chemical instability in the drug
isolation/development process (Fig. 4).
We have already reported some of our efforts on the site-
specific chemical modification of FR901469. In particular,
we have described selective direct modification of the
ornithine residue by synthesis of acylated and amidine
conjugates of the ornithine amino group [25,26], selective
functionalization of the tyrosine moiety [27] and complete
replacement of the ornithine by a novel substituted glutamic
acid residue [28]. In the course of these studies, it became
apparent that the hemolysis associated with the natural
product could be reduced significantly by chemical mod-
ification whilst maintaining the potent in vitro and, espe-
cially, in vivo antifungal activity. After completion of this
work, scientists at Nippon Roche described the discovery of
aerothricins, a series of lipopeptides closely related to
FR901469 [29]. A number of studies aimed at exploring
modifications at the ornithine moiety with a view to im-
proving the therapeutic index and antifungal potency have
also appeared recently [30,31].
As a part of continuing studies on FR901469, in order to
remove the propensity for ring opening leading to a bio-
logically inactive linear peptide, we designed the amide
analog of the natural product (Fig. 4). This design is a
rational one since an amide bond is significantly more stable
to hydrolysis compared to an ester, however, it was unclear
how such a modification would effect biological activity. On
the assumption of retention of activity, we were particularly
interested in the possibility of development of new method-
ology that would be applicable to the synthesis of a variety
of novel lipophilic side chain-modified analogs, since work
in the echinocandin B area established the influence of
lipophilicity of the acyl side chain on antifungal potency
and hemolysis of lipopeptides [24].
We based our approach to the synthesis of the amide
analog of FR901469 on deacylation of the lipophilic side
chain of the natural product, introduction of a pre-formed
amide-substituted side chain moiety, macrolactamization
and ornithine amino group deprotection. The key linear
peptide intermediate was produced in 35% yield by direct
incubation of FR901469 with Actinoplanes utahensis IFO-
13244 in 0.2 M phosphate at pH 7.8 and 60 jC (Fig. 5).
This organism has been employed for deacylation of various
lipopeptide compounds, including echinocandin B, and
cleaves only the amide bond connecting the lipophilic side
chain to the peptide skeleton [32]. In this work, we have
demonstrated another feature of this organism, whereby
simultaneous removal of a h-hydroxyacid side chain and
an ornithine moiety is also possible [33].
For this synthesis, the appropriate side-chain fragment
was prepared as shown (Fig. 6). Myristylaldehyde was
converted over six synthetic steps to an activated ester
Table 2
Biological properties of FR901469
Compound Hemolysis C. albicans FP633 A. fumigatus FP1305
MLC
(Ag/ml)
MIC
(Ag/ml)
ED50
(mg/kg/day)
ED50
(mg/kg/day)
FR901469 250 0.1 0.4 0.42
Echinocandin B 125 2.5 >32 >100
Fluconazole NT >100 >20 >40
Amphotericin B < 50 0.39 0.13 0.13
Fig. 4. Intramolecular ring-opening of FR901469.
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building block containing all required functionality. The h-
amino acid portion of the fragment was prepared by
adaptation of Davies methodology. The final steps in the
synthesis of the amide analog of FR901469 are shown in
Fig. 7. Acylation of the linear peptide produced by micro-
bial biotransformation with the activated synthetic dipep-
tide, followed by protecting group manipulation, macro-
cyclization under high dilution conditions and removal of
the tert-butoxycarbonyl (BOC) protecting group afforded
the amide analog (FR207010) as the hydrochloride salt after
ion-exchange chromatography and freeze-drying. In support
of our original expectations, this compound was signifi-
cantly more stable compared to FR901469 under high pH
conditions, and the antifungal potency was comparable to
the lactone natural product (Table 3).
Whilst FR207010 displayed comparable antifungal activ-
ity to FR901469, the presence of a linear unbranched
lipophilic side chain meant that hemolysis was still high.
This methodology is readily applicable to the synthesis of a
variety of novel lipophilic side chain-modified analogs, and
indeed, synthesis and biological activity of such analogs has
revealed that nonhemolytic compounds with natural prod-
uct-like levels of antifungal activity can be identified in this
series (data not shown).
4. Discovery and biological activity of FR901379 and
FK463, novel water-soluble echinocandin derivatives
The first example of a naturally occurring, water-soluble
echinocandin-like lipopeptide, FR901379 (Table 4), was
isolated from the culture broth of Coleophoma empetri F-
11899 [18,19]. This compound was originally designated
WF11899A and is one member of a family of three related
cyclic hexapeptides (WF11899A, B, C) that differ only in
the number of hydroxyl groups on the hexapeptide skeleton.
FR901379 is a cyclic hexapeptide bearing a fatty acid acyl
group on the N-terminal moiety and has excellent water-
solubility by virtue of the presence of a sulfonate moiety on
the homotyrosine residue. The water-solubility is greater
than 50 mg/ml, which is much higher than the water-
solubility of echinocandin B (0.008 mg/ml). FR901379
Fig. 5. Microbial deacylation of FR901469.
Fig. 6. FR901469 amide analog: activated ester fragment.
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displayed more potent inhibition of h-1,3-glucan synthase
from C. albicans 6406 (IC50 = 0.7 Ag/ml) than echinocandin
B (IC50 = 2.6 Ag/ml), and in a C. albicans murine infection
model, displayed a superior protective effect relative to
echinocandin B and fluconazole, but was weaker than
amphotericin B (Table 5). However, this compound was
not strongly effective in prolonging survival in a model of
disseminated aspergillosis, and it had an MLC of 62 Ag/ml,
indicating that chemical modification would be required to
improve antifungal potency and to reduce hemolysis.
Recently, scientists at Lilly reported that the in vivo, but
not in vitro, activity of cilofungin, an echinocandin B
derivative with a modified fatty acid side chain, against
Aspergillus fumigatus correlated with inhibition of A. fumi-
gatus glucan synthase [34], and that the hemolytic potential
of echinocandin B could be reduced by incorporation of
benzoyl-type side chains. In our studies, enyzmatic deacy-
lation of FR901379 was readily achieved and reacylation of
the resulting key skeleton, FR179642, afforded novel side
chain-modified antifungal agents. FR131535 [35,36] was
the first key compound prepared and displayed excellent
antifungal activity, comparable to FR901379, but without
the hemolysis associated with the natural product. Subse-
quent optimization studies were then initiated, leading
ultimately to the discovery of a novel analog, FK463, with
an excellent profile. The synthesis of FK463 is outlined in
Fig. 8, and involves a straightforward reacylation of the
hexapeptide skeleton FR179642 with a pre-formed novel
isoxazole-containing benzoyl-like side-chain [37]. In com-
Fig. 7. FR901469 amide analog: completion of synthesis.
Table 3
Antifungal activity of FR207010, the amide analog of FR901469
Fungal Species MIC (Ag/ml)
FR207010 FR901469 Amp-B Fluconazole
C. albicans ATCC90028 1 0.5 0.5 0.5
C. tropicalis TIMM0313 2 1 0.5 4
C. krusei ATCC6258 1 0.5 1 32
C. guilliermondii ATCC9390 1 0.5 0.5 4
C. parapsilosis ATCC22019 4 2 0.5 2
A. fumigatus TIMM0063 1 0.5 0.5 >64
A. niger ATCC6275 0.5 0.25 0.25 >64
Table 4
FR901379: a water-soluble echinocandin lipopeptide
h-1,3-glucan synthase inhibition (from C. albicans 6406)
Compound IC50 (Ag/ml)
FR901379 0.7
FR901469 0.05
Echinocandin B 2.6
Cilofungin 2.9
Papulacandin B 2.5
D. Barrett / Biochimica et Biophysica Acta 1587 (2002) 224–233 229
mon with FR901379 and FR131535, FK463 displays excel-
lent water-solubility.
Biological evaluation of FK463 has revealed that it
possesses potent in vitro antifungal activity [38–41]. In
comparison to the established agents, amphotericin B,
itraconazole and fluconazole, FK463 displayed excellent
activity against Candida species (Table 6) and Aspergillus
species (Table 7). In common with other 1,3-h-D-glucan
synthase inhibitors, FK463 was not active against Crypto-
coccus neoformans strains. [37]. FK463 was shown to be
fungicidal to C. albicans FP633 by examination of the
relationship between change in viable cell counts and drug
concentration after exposure for 24 h in comparison to other
drugs. A 99% or greater reduction in viability was observed
after 24 h of exposure to >0.0156 Ag/ml of FK463 (Fig. 9).
As can be seen from the data in Fig. 9, FK463 exhibited
fungicidal activity at concentrations lower than those at
which amphotericin B was fungicidal, and was clearly
superior to itraconazole and fluconazole, which displayed
fungistatic effects.
The in vivo antifungal efficacy of FK463 is also good
when drug is administered as an intravenous injection
(Table 8). In murine models of disseminated candidiasis
and aspergillosis, FK463 displayed comparable efficacy to
amphotericin B, and superior efficacy compared to fluco-
nazole [42]. In particular, in the candidiasis model, FK463
significantly prolonged the survival of intravenously in-
fected mice at doses of 0.125 mg/kg of body weight or
higher. In the disseminated aspergillosis model, FK463
given at doses of 0.5 mg/kg or higher significantly pro-
longed the survival of mice infected intravenously with A.
fumigatus conidia. This result indicates that the efficacy of
FK463 was about two times inferior to that of amphotericin
B. Furthermore, FK463 has demonstrated good in vivo
activity in mouse models of pulmonary aspergillosis [43].
Pulmonary aspergillosis in mice was induced by intranasal
inoculation and administration was by the intravenous route.
Table 5
Biological properties of FR901379
Compound Hemolysis C. albicans FP633 A. fumigatus FP1305
MLC
(Ag/ml)
MIC
(Ag/ml)
ED50
(mg/kg/day)
ED50
(mg/kg/day)
FR901379 62 0.2 1.8 70
Echinocandin B 125 2.5 >32 >100
Fluconazole NT >100 >20 >40
Amphotericin B < 50 0.39 0.13 0.13
Fig. 8. Deacylation of FR901379 and synthesis of FK463.
Table 6
Antifungal spectrum of FK463 (1)
Organism MIC (Ag/ml)
FK463 Amp-B ITCZ FLCZ
Candida albicans ATCC90028 0.0156 0.5 0.0313 0.5
Candida tropicalis TIMM0313 0.0313 0.5 0.125 4
Candida glabrata ATCC90030 0.0156 0.5 1 16
Candida kefyr ATCC28838 0.125 0.5 0.0625 0.5
Candida krusei ATCC6258 0.125 1 0.25 32
Candida guilliermondii ATCC9390 0.125 0.5 0.25 4
Candida parapsilosis ATCC22019 2 0.5 0.25 2
Candida stellatoidea IFM5491 0.0313 0.0625 0.0078 0.125
Saccharomyces cerevisiae ATCC9763 0.125 0.5 0.25 2
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The 50% effective dose was in the range 0.26–0.51 mg/kg
of body weight, which was comparable to amphotericin B.
The minimum effective plasma FK463 concentration in
murine pulmonary aspergillosis was determined to be
0.55–0.80 Ag/ml by a viable-cell reduction assay in the
target organs [43]. Good protection against infection due to
azole-resistant C. albicans has also been described [44]. The
prophylactic effect of FK463 against Pneumocystis carinii
infection in the severe combined immunodeficient (SCID)
mouse model has also been described [45]. P. carinii is an
opportunistic pathogen that causes P. carinii-associated
pneumonia (PCP), a cause of morbidity and mortality in
immunocompromised patients. A recent summary article
describes all available biological and clinical evaluation
data, including pharmacokinetic data, for FK463 (micafun-
gin) [46]. FK463 is currently in late-stage phase III clinical
development.
5. Conclusions
The recent FDA approval of the Merck compound
caspofungin as a therapy for refractory invasive aspergillo-
sis has opened up the first chapter in a new era for antifungal
therapy [47]. The confirmation that 1,3-h-D-glucan synthase
inhibition can provide compounds with significant clinical
utility bodes well for the future of treatment of severe
systemic fungal infections. Our efforts in this area have
culminated in the identification of FK463 (micafungin).
This compound is in phase III clinical trials worldwide,
and a new drug application (NDA) has been filed recently in
Table 7
Antifungal spectrum of FK463 (2)
Organism MIC (Ag/ml)
FK463 Amp-B ITCZ FLCZ
Cryptococcus neoformans
TIMM0354
>64 0.25 0.0313 0.5
Trichosporon cutaneum IFM4-1-4 >64 2 0.5 8
Trichosporon asahii TIMM3144 >64 0.25 0.25 2
Aspergillus fumigatus TIMM0063 0.0078 0.5 0.5 >64
Aspergillus niger ATCC6275 0.0078 0.25 0.5 >64
Aspergillus nidulans IFM5369 0.0078 1 0.0625 32
Aspergillus flavus ATCC9643 0.0156 1 0.25 64
Aspergillus terreus IFM5369 0.0156 1 0.125 >64
Aspergillus versicolor IFM41406 0.0156 0.5 0.0625 32
Fusarium solani IFM41532 >64 0.25 >8 >64
Fig. 9. Fungicidal activity against C. albicans FP633 after 24-h exposure.
Table 8
In vivo efficacy of FK463: disseminated candidiasis and aspergillosis
Organism ED50 (mg/kg/day)
FK463 FLCZ Amp-B
C. albicans FP633 0.14 2.15 0.08
C. glabrata 13002 0.30 6.27 0.11
C. tropicalis 16009 0.28 3.71 0.09
C. krusei FP1866 0.77 9.52 0.26
C. parapsilosis FP1946 1.00 10.9 0.06
A. fumigatus IFM41209 0.50 >20 0.29
Once-daily treatment for 4 days starting 1 h after infection by intravenous
administration to mice.
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Japan. These developments clearly show that a rational
approach to antifungal drug discovery, focussing on com-
pounds that interfere selectively with elements essential to
the survival of fungal cells, can lead to new agents with the
potential to become key components in the arsenal of
weapons directed at serious systemic fungal disease.
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